Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
UCB bets $2 billion on Candid’s T cell engager ambitions
Ken Song has done it again. The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by


